Specifically, using CRISPR technology and lipid NPs, nearly complete hepatic suppression of the proprotein convertase subtilisin/kexin type 9 (PCSK9) gene—a factor increasing cardiovascular disease risk—was observed. This evidence concerns the gene PCSK9 and cardiovascular disorder.